SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer
Status:
Completed
Trial end date:
2003-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: SU5416 may stop the growth of breast cancer by stopping blood flow to the tumor.
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop
growing or die. Combining SU5416 with chemotherapy may kill more cancer cells.
PURPOSE: Phase I trial to study the effectiveness of combining SU5416 and doxorubicin in
treating patients who have stage IIIB or stage IV inflammatory breast cancer.